At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Splanchnic Nerve Block for Therapy of Chronic Heart Failure (Splanchnic III)
In Brief
A Phase 2 clinical trial evaluating Splanchnic nerve block for Chronic Heart Failure. Completed, enrolled 5 participants across 1 site.
Detailed Summary
Splanchnic vasoconstriction may contribute to decompensation of chronic heart failure (HF) via volume redistribution from the splanchnic vascular bed to the central compartment. This is a sympathetically mediated reflex and can be interrupted through a splanchnic nerve block (SNB). We hypothesize that interruption of the efferent/afferent innervation of the splanchnic vasculature will decrease cardiac congestion in patients presenting with HF. Based on preliminary safety and efficacy data in acute and chronic heart failure patients with temporary (\<24 h) SNB. Now we will apply a prolonged SNB in chronic heart failure patients using a long acting agent. We will test the effects of SNB on long term exercise capacitance.
Study Details
Timeline
Interventions
Percutaneous splanchnic nerve block